Case Comprehensive Cancer Center: Primary Myelofibrosis trials
The registry lists 12 Primary Myelofibrosis studies with Case Comprehensive Cancer Center as lead sponsor. 1 are open to participants now and 0 have results posted.
Early Phase 1 1Phase 1 4Phase 2 5Phase 3 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and ThrombocytopeniaNot yet recruitingNCT07936201Phase 2
- Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative NeoplasmsWithdrawnNCT04629651Phase 1/2
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
- Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell TransplantCompletedNCT00361049Phase 1
- Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow TransplantationCompletedNCT00281801
- Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative DisorderCompletedNCT00274820Phase 2
- Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
- Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic MalignanciesCompletedNCT00068523Not applicable
- Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaCompletedNCT00054236Phase 1
- Non-Ablative Allo HSCT For Hematologic Malignancies or SAACompletedNCT00006379Phase 2